Compare WFCF & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WFCF | TCRX |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.5M | 49.4M |
| IPO Year | 2006 | 2021 |
| Metric | WFCF | TCRX |
|---|---|---|
| Price | $12.50 | $0.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 4.3K | ★ 470.5K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $20,774,416.00 | $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.81 |
| P/E Ratio | $133.10 | ★ N/A |
| Revenue Growth | 16.69 | ★ 266.65 |
| 52 Week Low | $9.15 | $0.72 |
| 52 Week High | $22.15 | $2.57 |
| Indicator | WFCF | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.96 | 44.78 |
| Support Level | $12.01 | $0.73 |
| Resistance Level | $13.27 | $0.80 |
| Average True Range (ATR) | 0.63 | 0.04 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 25.21 | 50.25 |
Where Food Comes From Inc is a third-party food verification company conducting both on-site and desk audits to verify that claims being made about livestock, food, other high-value specialty crops and agricultural and aquaculture products are accurate. The company supports farmers, ranchers, vineyards, wineries, processors, retailers, distributors, trade associations, and restaurants with a wide variety of value-added services provided through its family of verifiers, including International Certification Services, Validus Verification Services, and others. It also provides a wide range of professional consulting services. It generates the majority of its revenue from Verification and certification services.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.